Sativex is the only regulatory-
approved cannabinoid treatment
for patients with MS spasticity1,2

Burden
of MS spasticity
Image
graph

MS spasticity
can have a major
impact on
patients’ quality
of life3,4

Spasticity can substantially impair patients’ ability to
perform even the most basic everyday tasks5

Item icon
Image
icon
Washing
Item icon
Image
icon
Mobility
Item icon
Image
icon
Housework
Item icon
Image
icon
Socialising
Item icon
Image
icon
Self-care
Item icon
Image
icon
Dressing
Item icon
Image
icon
Eating
Item icon
Image
icon
Work

Patients’ other MS symptoms worsen as their spasticity becomes more severe3

Effect of spasticity severity on patients’ mean MS symptom disability scores3

Image
graph
Image
test img

 

 

 

Sativex is an
oromucosal spray
containing a complex
botanical mixture
derived from the
Cannabis
sativa L. plant1,6

What is
Sativex?
Image
test img
Image
img
Each 100μl spray contains:

2.7mg

THC¹

THC acts upon neurons
throughout the body to help regulate
synaptic activity1,7,8

2.5mg

CBD¹

CBD may counteract some
of the negative psychological effects
associated with THC9,10

See how Sativex can give MS spasticity patients much-needed
symptom relief6,11–13

 

 

New
bottle and packaging
Image
box

GW Pharmaceuticals
developed and have always
manufactured Sativex.
Now we are increasing
engagement with patients and
healthcare professionals,
we have brought the
marketing and
commercialisation of
Sativex in-house, too

Listening to your feedback

 

We’ve added a blue marker to the nozzle so it’s easy for patients to direct the spray exactly where they want it.

 

Image
img

A fresh new look

 

We have updated the design of the packaging to reflect our new role in marketing Sativex.

 

Image
img

MS, multiple sclerosis.

References:
1. Sativex Summary of Product Characteristics.
2. NICE. NG144. November 2019.